Madrigal Pharmaceuticals, Inc. (MDGL), Thursday announced that its Phase 3 MAESTRO-NASH biopsy trial using Rezdiffra achieved both fibrosis improvement and NASH resolution primary endpoints. Further, 80 percent of patients treated with Rezdiffra 100 mg experienced improvement or stabilization of fibrosis.
Rezdiffra is a once-daily, oral, liver-directed thyroid hormone receptor -ß agonist and is targeted to key underlying causes of NASH. The company said the AI-based analysis of MAESTRO-NASH biopsy data might help in the prediction of progression to decompensated cirrhosis. Rezdiffra is currently indicated in conjunction with diet and exercise with noncirrhotic NASH with moderate to advanced liver fibrosis.
Madrigal noted that the noninvasive test data through three years of treatment demonstrate durable treatment response to Rezdiffra.
The results from Rezdiffra will be presented at the EASL Congress in Milan, Italy.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.